Sun Pharma Q2 Profit Falls 36% as Litigation and Deal Costs Weigh on Earnings
Sun Pharmaceutical Industries reported a 36% drop in second-quarter net profit to Rs 1,989 crore, as exceptional litigation and acquisition-related expenses sharply reduced earnings. Revenue rose 11.8% on the back of strong domestic and emerging-market demand, but weakness in the US formulations business tempered the overall performance.
